News

The company’s decision is backed by the company’s growth in the healthcare inductry from its origins in prescription drug pricing and purchasing technology to its expansion into broader

Researchers used the Roche’s cardio instrument to carry out dose-response profiling of 60 pharmaceutical drugs including the drugs withdrawn from the market due to TdP arrhythmia, hERG trafficking

Hiroshi Yamazaki has joined as a regional director of EvaluatePharma Japan KK, who will be responsible for development of EvaluatePharma’s business in Japan. EvaluatePharmaAlpha offers an off-the-shelf valuation

The rise was mainly attributable to year-over-year increase in average selling prices of the company’s products and the growing market acceptance of the Company’s new products introduced in

The new R&D center will house two of Covidien’s emerging market R&D organizations, Tailored Products and Breakthrough Platforms. Covidien China R&D vice president Dong Wu said they will

Factor VIIa is used to treat hemophilia A and B patients who have developed inhibitors against treatment with either Factor VIII or IX and are suferring from acute

With this plan, the company expects to seek approval for an initial indication that includes obese men and women of non-child bearing potential. The company intends to refile

The acquisition allows VBI to develop its own VLP-based vaccines by leveraging its suite of thermostable vaccine formulation technologies. The terms of the deal were not disclosed. VBI

Hyalgan is an injectable treatment for knee pain associated with osteoarthritis when simple painkillers or exercise and physical therapy are not enough. Following the transfer of the rights,